Lantern Pharma (LTRN) Capital Expenditures (2021 - 2025)
Lantern Pharma's (LTRN) quarterly Capital Expenditures came in at $1.0 in Q4 2025, down 99.97% YoY from $3083.0 in Q4 2024, and down 99.82% on a QoQ basis from $555.0 in Q3 2025.
Lantern Pharma (LTRN) Capital Expenditures (2021 - 2025) Analysis & Trends
Lantern Pharma (LTRN) has 5 years of Capital Expenditures data on file, last reported at $1.0 in Q4 2025.
- Quarterly Capital Expenditures fell 99.97% year-over-year to $1.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1715.0 (down 86.38% YoY) and the FY2025 annual result came in at $1715.0, down 86.38% from the prior year.
- Capital Expenditures slipped to $1.0 in Q4 2025, from $555.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $8876.0 in Q1 2023 to a low of $1.0 in Q4 2021.
- A 5-year average of $3585.4 and a median of $3283.5 in 2021 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures jumped 695400.0% — and 2025, when it tumbled 99.97%.
- Tracing LTRN's Capital Expenditures over 5 years: stood at $1.0 in 2021, then jumped by 695400.0% to $6955.0 in 2022, then declined by 26.94% to $5081.0 in 2023, then tumbled by 39.32% to $3083.0 in 2024, then plunged by 99.97% to $1.0 in 2025.
- The last three Capital Expenditures figures came in at $1.0 (Q4 2025), $555.0 (Q3 2025), and $1159.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | Lantern Pharma | 26.11 Mn | 26.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.00 |
| Dec 31, 2025 | 1.00 |
| Sep 30, 2025 | 555.00 |
| Sep 30, 2025 | 555.00 |
| Mar 31, 2025 | 1,159.00 |
| Mar 31, 2025 | 1,159.00 |
| Dec 31, 2024 | 3,083.00 |
| Dec 31, 2024 | 3,083.00 |
| Sep 30, 2024 | 3,028.00 |
| Sep 30, 2024 | 3,028.00 |
| Jun 30, 2024 | 4,267.00 |
| Jun 30, 2024 | 4,267.00 |
| Mar 31, 2024 | 2,217.00 |
| Mar 31, 2024 | 2,217.00 |
| Dec 31, 2023 | 5,081.00 |
| Dec 31, 2023 | 5,081.00 |
| Sep 30, 2023 | 4,777.00 |
| Sep 30, 2023 | 4,777.00 |
| Mar 31, 2023 | 8,876.00 |
| Mar 31, 2023 | 8,876.00 |